Bampidis Vasileios, Azimonti Giovanna, Bastos Maria de Lourdes, Christensen Henrik, Dusemund Birgit, Kouba Maryline, Fašmon Durjava Mojca, López-Alonso Marta, López Puente Secundino, Marcon Francesca, Mayo Baltasar, Pechová Alena, Petkova Mariana, Ramos Fernando, Sanz Yolanda, Villa Roberto Edoardo, Woutersen Ruud, Cocconcelli Pier Sandro, Glandorf Boet, Maradona Miguel Prieto, Saarela Maria, Galobart Jaume, Gregoretti Lucilla, Innocenti Matteo, López-Gálvez Gloria, Vettori Maria Vittoria, Brozzi Rosella
EFSA J. 2021 Mar 8;19(3):e06451. doi: 10.2903/j.efsa.2021.6451. eCollection 2021 Mar.
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of the additive consisting of DSM 7134 (trade name: Bonvital) as a zootechnical additive (gut flora stabiliser) for chickens for fattening. The additive is produced in powder and granulate (microencapsulated) forms. The applicant has provided data demonstrating that the additive currently in the market complies with the conditions of authorisation. The FEEDAP Panel confirms that the use of Bonvital under the current authorised conditions of use is safe for the target species, the consumers and the environment. Bonvital is not irritant to skin and eyes but should be considered a potential skin sensitiser and a respiratory sensitiser. There is no need to assess the efficacy of Bonvital in the context of the renewal of the authorisation. The FEEDAP Panel reiterates its previous conclusions that DSM 7134 is compatible with the coccidiostats robenidine hydrochloride, maduramicin ammonium, diclazuril, decoquinate, halofuginone hydrobromide, monensin sodium and lasalocid A sodium.
应欧盟委员会的要求,动物饲料添加剂及产品或物质专家小组(FEEDAP)被要求就由帝斯曼7134(商品名:Bonvital)组成的添加剂作为育肥鸡的动物技术添加剂(肠道菌群稳定剂)的授权续展申请评估发表科学意见。该添加剂有粉末和颗粒(微囊化)两种形式。申请人提供的数据表明,目前市场上的该添加剂符合授权条件。FEEDAP专家小组确认,在当前授权使用条件下使用Bonvital对目标物种、消费者和环境是安全的。Bonvital对皮肤和眼睛无刺激性,但应被视为潜在的皮肤致敏剂和呼吸道致敏剂。在授权续展的背景下,无需评估Bonvital的功效。FEEDAP专家小组重申其先前的结论,即帝斯曼7134与抗球虫药盐酸氯苯胍、马杜霉素铵、地克珠利、癸氧喹酯、氢溴酸常山酮、莫能菌素钠和拉沙洛西钠A兼容。